Original Study| Volume 11, ISSUE 2, P120-127, February 2010

Download started.


Antipsychotic Use and the Risk of Hip Fracture Among Older Adults Afflicted With Dementia

Published:January 13, 2010DOI:


      To quantify the association between use of antipsychotic (AP) medications and the risk of hip fracture among older adults residing in a nursing home (NH) and afflicted with dementia.


      Nested case-control study.


      NHs in California, Florida, Illinois, New York, and Ohio in 2001–2002 (N=586).


      The source population consisted of long-stay Medicaid-eligible residents living in NHs with at least 20 beds, who were 65 years of age or older and had a diagnosis of dementia but were not receiving hospice care, were not comatose, bedfast, paralyzed, or in a wheelchair, and had no record of a previous hip fracture (N=69,027). There were 764 cases of hip fracture identified; up to 5 controls, matched to cases on NH and quarter of Minimum Data Set (MDS) assessment, were randomly selected from the source population (N=3582).


      Cases of hip fracture were identified and medication use was ascertained from Medicaid claims data. Resident-level characteristics, including dementia severity, were obtained from resident MDS assessments.


      Current use of APs conveyed a small increased risk of hip fracture (adjusted odds ratio=1.26; 95% confidence interval: 1.05 –1.52). When analyzed separately, users of conventional antipsychotics had a slightly higher risk of hip fracture than residents on atypical agents. Long-term use of APs conferred a greater risk of hip fracture than short-term use.


      APs appear to increase the risk of hip fracture among older adults with dementia residing in an NH. Hip fractures may be a contributory mechanism to the increased risk mortality observed among AP users.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Cummings J.L.
        Alzheimer's disease.
        N Engl J Med. 2004; 351: 56-67
        • Jalbert J.J.
        • Daiello L.A.
        • Lapane K.L.
        Dementia of the Alzheimer type.
        Epidemiol Rev. 2008; 30: 15-34
      1. Food and Drug Administration. Information for Healthcare Professionals: Antipsychotics. Available at: Accessed October 5, 2009.

        • Schneider L.S.
        • Dagerman K.S.
        • Insel P.
        Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials.
        JAMA. 2005; 294: 1934-1943
        • Kales H.C.
        • Valenstein M.
        • Kim H.M.
        • et al.
        Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications.
        Am J Psychiatry. 2007; 164: 1568-1576
        • Schneeweiss S.
        • Setoguchi S.
        • Brookhart A.
        • et al.
        Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.
        CMAJ. 2007; 176: 627-632
        • Hollis J.
        • Grayson D.
        • Forrester L.
        • et al.
        Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older.
        Am J Geriatr Psychiatry. 2007; 15: 932-941
        • Trifiro G.
        • Verhamme K.M.
        • Ziere G.
        • et al.
        All-cause mortality associated with atypical and typical antipsychotics in demented outpatients.
        Pharmacoepidemiol Drug Saf. 2007; 16: 538-544
        • Gill S.S.
        • Bronskill S.E.
        • Normand S.L.
        • et al.
        Antipsychotic drug use and mortality in older adults with dementia.
        Ann Intern Med. 2007; 146: 775-786
        • Wang P.S.
        • Schneeweiss S.
        • Avorn J.
        • et al.
        Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
        N Engl J Med. 2005; 353: 2335-2341
        • Liperoti R.
        • Gambassi G.
        • Lapane K.L.
        • et al.
        Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics.
        J Clin Psychiatry. 2005; 66: 1090-1096
        • Herrmann N.
        • Mamdani M.
        • Lanctot K.L.
        Atypical antipsychotics and risk of cerebrovascular accidents.
        Am J Psychiatry. 2004; 161: 1113-1115
        • Liperoti R.
        • Pedone C.
        • Lapane K.L.
        • et al.
        Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents.
        Arch Intern Med. 2005; 165: 2677-2682
        • Knol W.
        • van Marum R.J.
        • Jansen P.A.
        • et al.
        Antipsychotic drug use and risk of pneumonia in elderly people.
        J Am Geriatr Soc. 2008; 56: 661-666
        • Ray W.A.
        • Chung C.P.
        • Murray K.T.
        • et al.
        Atypical antipsychotic drugs and the risk of sudden cardiac death.
        N Engl J Med. 2009; 360: 225-235
        • Liperoti R.
        • Gambassi G.
        • Lapane K.L.
        • et al.
        Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.
        Arch Intern Med. 2005; 165: 696-701
        • Straus S.M.
        • Bleumink G.S.
        • Dieleman J.P.
        • et al.
        Antipsychotics and the risk of sudden cardiac death.
        Arch Intern Med. 2004; 164: 1293-1297
        • Davidson C.W.
        • Merrilees M.J.
        • Wilkinson T.J.
        • et al.
        Hip fracture mortality and morbidity—can we do better?.
        N Z Med J. 2001; 114: 329-332
        • White B.L.
        • Fisher W.D.
        • Laurin C.A.
        Rate of mortality for elderly patients after fracture of the hip in the 1980's.
        J Bone Joint Surg Am. 1987; 69: 1335-1340
        • Haleem S.
        • Lutchman L.
        • Mayahi R.
        • et al.
        Mortality following hip fracture: Trends and geographical variations over the last 40 years.
        Injury. 2008; 39: 1157-1163
        • Morrison R.S.
        • Siu A.L.
        Survival in end-stage dementia following acute illness.
        JAMA. 2000; 284: 47-52
        • Morris J.N.
        • Hawes C.
        • Fries B.E.
        • et al.
        Designing the national resident assessment instrument for nursing homes.
        Gerontologist. 1990; 30: 293-307
        • Hawes C.
        • Morris J.N.
        • Phillips C.D.
        • et al.
        Reliability estimates for the Minimum Data Set for nursing home resident assessment and care screening (MDS).
        Gerontologist. 1995; 35: 172-178
        • Lawton M.P.
        • Casten R.
        • Parmelee P.A.
        • et al.
        Psychometric characteristics of the minimum data set II: Validity.
        J Am Geriatr Soc. 1998; 46: 736-744
        • Hartmaier S.L.
        • Sloane P.D.
        • Guess H.A.
        • et al.
        The MDS Cognition Scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set.
        J Am Geriatr Soc. 1994; 42: 1173-1179
        • Gambassi G.
        • Landi F.
        • Peng L.
        • et al.
        Validity of diagnostic and drug data in standardized nursing home resident assessments: Potential for geriatric pharmacoepidemiology. SAGE Study Group. Systematic Assessment of Geriatric drug use via Epidemiology.
        Med Care. 1998; 36: 167-179
        • Morris J.N.
        • Nonemaker S.
        • Murphy K.
        • et al.
        A commitment to change: Revision of HCFA's RAI.
        J Am Geriatr Soc. 1997; 45: 1011-1016
        • Hennessy S.
        • Carson J.L.
        • Ray W.A.
        • Strom B.L.
        Medicaid Databases.
        in: Strom B.L. Pharmacoepidemiology. 4th ed. John Wiley & Sons, Hoboken, NJ2005
        • Department of Health and Human Services
        Medicaid At-A-Glance 2005: A Medicaid Information Source.
        Centers for Medicare and Medicaid Services, Baltimore, MD2005 (DHHS publication no. (CMS) 11024–05)
        • McKenzie D.A.
        • Semradek J.
        • McFarland B.H.
        • et al.
        The validity of Medicaid pharmacy claims for estimating drug use among elderly nursing home residents: The Oregon experience.
        J Clin Epidemiol. 2000; 53: 1248-1257
        • Ngo D.L.
        • Marshall L.M.
        • Howard R.N.
        • et al.
        Agreement between self-reported information and medical claims data on diagnosed diabetes in Oregon's Medicaid population.
        J Public Health Manag Pract. 2003; 9: 542-544
        • Federspiel C.F.
        • Ray W.A.
        • Schaffner W.
        Medicaid records as a valid data source: The Tennessee experience.
        Med Care. 1976; 14: 166-172
        • Wysowski D.K.
        • Baum C.
        The validity of Medicaid diagnoses of hip fracture.
        Am J Public Health. 1993; 83: 770
        • Ray W.A.
        • Griffin M.R.
        • Fought R.L.
        • Adams M.L.
        Identification of fractures from computerized Medicare files.
        J Clin Epidemiol. 1992; 45: 703-714
      2. Matthews R, Brill I. SAS Programs to Select Controls for Matched Case-Control Studies SAS Users Group International Paper 152–130.

      3. Prescription drug coverage under Medicaid 2008. Congressional Research Service Report for Congress 2008. Hearne J (online). Available at: Accessed October 5, 2009.

        • Clinical Guidelines on the Identification
        Evaluation, and Treatment of Overweight and Obesity in Adults—The Evidence Report. National Institutes of Health.
        Obes Res. 1998; 6 (51S–209S)
        • Katz S.
        • Moskowitz R.W.
        • Jackson B.A.
        • et al.
        Studies of illness in the aged, the index of ADL: a standardized measure of biological and psychosocial function.
        JAMA. 1963; 185: 94-99
        • Liperoti R.
        • Onder G.
        • Lapane K.L.
        • et al.
        Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: Results of a case-control study.
        J Clin Psychiatry. 2007; 68: 929-934
        • Pouwels S.
        • van Staa T.P.
        • Egberts A.C.
        • et al.
        Antipsychotic use and the risk of hip/femur fracture: A population-based case-control study.
        Osteoporos Int. 2009; 20: 1499-1506
        • Hugenholtz G.W.
        • Heerdink E.R.
        • van Staa T.P.
        • et al.
        Risk of hip/femur fractures in patients using antipsychotics.
        Bone. 2005; 37: 864-870
        • Howard L.
        • Kirkwood G.
        • Leese M.
        Risk of hip fracture in patients with a history of schizophrenia.
        Br J Psychiatry. 2007; 190: 129-134
        • Wang P.S.
        • Bohn R.L.
        • Glynn R.J.
        • et al.
        Zolpidem use and hip fractures in older people.
        J Am Geriatr Soc. 2001; 49: 1685-1690
        • Vestergaard P.
        • Rejnmark L.
        • Mosekilde L.
        Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture.
        Osteoporos Int. 2006; 17: 807-816
        • Kolanowski A.
        • Fick D.
        • Waller J.L.
        • Ahern F.
        Outcomes of antipsychotic drug use in community-dwelling elders with dementia.
        Arch Psychiatr Nurs. 2006; 20: 217-225
        • Takkouche B.
        • Montes-Martinez A.
        • Gill S.S.
        • Etminan M.
        Psychotropic medications and the risk of fracture: A meta-analysis.
        Drug Saf. 2007; 30: 171-184
        • Drici M.D.
        • Priori S.
        Cardiovascular risks of atypical antipsychotic drug treatment.
        Pharmacoepidemiol Drug Saf. 2007; 16: 882-890
        • Gupta S.
        • Masand P.
        • Madhusoodanan S.
        Side effects of atypical antipsychotics in the geriatric population.
        Current Psychosis and Therapeutics Reports. 2005; 3: 26-31
        • Becker D.
        • Liver O.
        • Mester R.
        • et al.
        Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients.
        J Clin Psychiatry. 2003; 64: 761-766
        • Meaney A.M.
        • Smith S.
        • Howes O.D.
        • et al.
        Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia.
        Br J Psychiatry. 2004; 184: 503-508
        • O'Keane V.
        Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
        J Psychopharmacol. 2008; 22: 70-75
        • Ray W.A.
        Evaluating medication effects outside of clinical trials: new-user designs.
        Am J Epidemiol. 2003; 158: 915-920
        • Briesacher B.A.
        • Limcangco M.R.
        • Simoni-Wastila L.
        • et al.
        The quality of antipsychotic drug prescribing in nursing homes.
        Arch Intern Med. 2005; 165: 1280-1285